Biotechnology Regulatory Law In Ukraine.
1. Introduction
Biotechnology Regulatory Law in Ukraine is a developing area of law governing the research, development, production, testing, registration, commercialisation and distribution of biotechnology products and processes.
It regulates activities involving:
Genetic engineering and genetically modified organisms (GMOs).
Gene editing and recombinant DNA technology.
Biotechnology-based medicines and vaccines.
Stem-cell research and regenerative medicine.
Genomic research and genetic testing.
Agricultural biotechnology and genetically modified crops.
Industrial biotechnology and biological manufacturing.
Clinical trials and biological safety.
Biotechnology patents and intellectual property.
Protection of human health, genetic information and the environment.
Ukraine's biotechnology regulatory framework combines national legislation, European Union regulatory principles, international biosafety obligations and judicial review.
An important legislative development: Ukraine adopted Law No. 3339-IX of 23 August 2023 on State Regulation of Genetic Engineering Activities and State Control over the Placing on the Market of GMOs and Products. It replaced the earlier GMO Biosafety Law No. 1103-V from 16 September 2026. Consequently, the new law is the principal starting point for analysing GMO regulation as of November 2026.
CIS Legislation+1
2. Constitutional foundations of biotechnology regulation
The Constitution of Ukraine provides the overarching legal framework for biotechnology regulation.
Several constitutional principles are particularly important.
A. Right to health protection
Article 49 protects the right to healthcare and medical assistance. This principle is relevant to biotechnology-based medicines, vaccines, genetic therapies and regenerative medical treatments.
B. Environmental protection
Article 50 recognises the right to an environment safe for life and health and the right to compensation for damage caused by violations of this right.
This is relevant to:
Accidental GMO releases.
Genetic contamination of agricultural crops.
Unsafe biological waste disposal.
Environmental risks arising from genetically engineered organisms.
C. Scientific freedom
Article 54 protects freedom of scientific and technical creativity. Biotechnology researchers therefore enjoy constitutional protection, subject to applicable safety, ethical and regulatory restrictions.
D. Human dignity and privacy
Articles 28 and 32 protect human dignity, personal integrity and privacy. These principles become particularly important in genetic testing, human biological sample collection, genomic databases and experimental treatments.
The constitutional framework requires a balance between scientific freedom, public health, individual rights and environmental protection.
3. Principal biotechnology legislation in Ukraine
The Ukrainian regulatory framework is not contained in one comprehensive biotechnology statute. Different laws regulate different stages of biotechnology development.
| Legislation | Principal regulatory subject |
|---|---|
| Law No. 3339-IX (2023) | Genetic engineering and GMO regulation |
| Law No. 2042-VIII (2017) | State control of food and feed safety |
| Law No. 771/97-VR (1997) | Food safety and quality |
| Law No. 123/96-VR (1996) | Medicinal products |
| Law No. 2801-XII (1992) | Fundamentals of healthcare legislation |
| Law No. 2297-VI (2010) | Personal data protection |
| Law No. 3687-XII (1993) | Inventions and utility models |
| Law No. 2059-VIII (2017) | Environmental impact assessment |
The precise applicable requirements depend on whether the activity concerns human medicine, agricultural biotechnology, industrial biotechnology, food production or genetic engineering.
zakon.rada.gov.ua+2
4. Regulation of genetic engineering and GMOs
Principal legislation
Law No. 3339-IX of 23 August 2023
The law establishes the legal and organisational framework for regulating genetic engineering activities and controlling the placing of genetically modified organisms and products on the Ukrainian market.
It addresses four important objectives:
Protection of human health.
Protection of biodiversity and the environment.
Prevention of genetic and biological risks.
Regulation of commercial activities involving GMOs.
A. Closed-system genetic engineering
Closed-system activities are conducted in controlled facilities, such as biotechnology laboratories, research institutions and industrial production facilities.
Examples include:
Recombinant DNA experiments.
Genetic modification of microorganisms.
Production of recombinant proteins.
Genetically engineered bacterial cultures.
Laboratory development of gene therapies.
Regulatory compliance involves appropriate containment, laboratory safety, risk assessment, staff competence and waste-management procedures.
The law provides for government supervision of biosafety in contained genetic engineering activities.
B. Open-system genetic engineering
Open-system activities involve potential contact between genetically modified organisms and the external environment.
Examples include:
Field testing of genetically modified crops.
Cultivation of genetically engineered plants.
Environmental release experiments.
Testing genetically modified microorganisms outside contained facilities.
These activities require consideration of environmental exposure, biological containment, monitoring and appropriate protective measures.
C. State registration of GMOs
State registration is a central regulatory requirement.
A GMO cannot ordinarily be placed on the Ukrainian market unless it has been registered for the relevant intended use.
The regulatory process involves:
Identification of the GMO.
Scientific and technical information.
Risk assessment.
Evaluation of intended use.
Examination of relevant safety evidence.
Entry into the State Register of GMOs.
Registration for one purpose does not automatically authorise every other possible use.
D. Commercialisation and market surveillance
The legislation covers commercial possession, distribution, sale and other forms of transfer of GMO products.
The production and cultivation of genetically modified plants are also treated as market-placement activities under the new law.
Businesses must maintain traceability documentation and comply with registration, declaration and labelling requirements.
In particular, the first person placing GMO products on the market must prepare a declaration containing relevant operator and GMO registration information.
These requirements are important for agricultural biotechnology companies, food manufacturers, seed suppliers and importers.
consumerhm.gov.ua+2
5. Regulatory authorities and institutional responsibilities
Biotechnology regulation in Ukraine involves several public authorities.
| Authority | Principal responsibility |
|---|---|
| Ministry of Health | Public health, medical products and relevant biosafety matters |
| Ministry of Economy and Environment | GMO registration and environmental and economic policy responsibilities under the applicable framework |
| State Production and Consumer Service | Food safety, market controls and consumer protection |
| Environmental inspection authorities | Environmental compliance and GMO-related environmental supervision |
| Ukrainian patent authorities | Patent examination and intellectual property protection |
| Cabinet of Ministers | Adoption of implementing regulations and coordination of executive authorities |
The precise division of responsibility depends on the type of biotechnology activity.
For example, the supervision of contained laboratory genetic engineering is different from the supervision of commercial GMO products or the environmental release of genetically modified plants.
The new law also aims to reduce overlapping responsibilities among regulatory institutions.
Офіційний портал Верховної Ради України+2
6. Biotechnology medicines and pharmaceutical regulation
Biotechnology-based medicinal products are regulated through Ukraine's pharmaceutical and healthcare legislation.
The principal legislation includes:
Law No. 123/96-VR on Medicinal Products.
Law No. 2801-XII on Fundamentals of Ukrainian Healthcare Legislation.
Applicable Ministry of Health regulations.
Rules governing pharmaceutical manufacturing and quality assurance.
Biological medicines include:
Recombinant insulin.
Monoclonal antibodies.
Recombinant vaccines.
Blood-derived medicinal products.
Recombinant growth hormones.
Cell-based medicinal products.
Certain gene-therapy products.
A. Registration of biotechnology medicines
A biotechnology medicine generally requires the applicable state registration before it can be marketed.
The registration assessment considers:
Quality of the medicinal product.
Manufacturing consistency.
Biological activity.
Safety.
Clinical evidence.
Stability and storage.
Manufacturing controls.
Biological medicines require particular attention because their manufacturing processes can influence their molecular characteristics and biological activity.
B. Good Manufacturing Practice
Biotechnology manufacturers must comply with applicable pharmaceutical manufacturing requirements.
GMP compliance is important for:
Sterile biological products.
Vaccine manufacturing.
Recombinant proteins.
Cell-culture production.
Biological quality testing.
Contamination prevention.
A manufacturer cannot treat laboratory success as sufficient evidence of commercial pharmaceutical compliance.
C. Biosimilars
Biosimilars are biological medicines demonstrated to be highly similar to an authorised reference biological medicine, subject to applicable regulatory requirements.
Their assessment may involve:
Structural characterisation.
Biological activity.
Comparative analytical studies.
Pharmacokinetic and pharmacodynamic evidence.
Clinical evidence where required.
Immunogenicity evaluation.
The regulatory objective is to establish that the biosimilar meets the relevant standards of quality, safety and efficacy.
7. Clinical trials and biotechnology research
Clinical research is another important component of Ukrainian biotechnology law.
Research involving biotechnology medicines, vaccines, gene therapies and other innovative biological treatments must comply with the applicable clinical-trial and medical ethics requirements.
Important legal requirements
A. Prior authorisation
Clinical trials of medicinal products must follow the applicable authorisation and approval procedures.
B. Informed consent
Participants must receive appropriate information concerning:
The purpose of the study.
Experimental treatment procedures.
Potential risks.
Expected benefits.
Available alternatives.
Their right to withdraw.
C. Ethics committee review
The research must undergo the required ethical review, including consideration of participant safety, scientific justification and consent procedures.
D. Protection of vulnerable participants
Special safeguards apply to research involving children and persons who cannot independently provide legally effective consent.
E. Research documentation
Researchers and sponsors must maintain appropriate records of study protocols, adverse events, safety monitoring and research results.
Legal significance
A biotechnology company cannot avoid clinical-trial obligations merely by describing its product as an experimental biological preparation or innovative scientific technology.
The legal classification of the product and activity determines which regulatory requirements apply.
8. Genetic data protection and genomic privacy
Genetic information creates particular legal concerns because it may reveal information about an individual's health, ancestry and biological characteristics.
Ukraine's Law No. 2297-VI on Personal Data Protection provides the general statutory framework for personal-data processing.
Biotechnology research institutions must consider:
Lawful grounds for collecting personal information.
Informed consent where required.
Purpose limitation.
Data confidentiality.
Security of genomic databases.
Appropriate disclosure controls.
Cross-border data-transfer requirements.
Genetic information may also reveal information about biological relatives who have not directly participated in a genetic study.
This creates difficult questions concerning familial privacy, genetic counselling, secondary use of samples and the disclosure of hereditary risks.
Example: A biotechnology company collects blood samples from 1,000 volunteers for genomic research. It later decides to use the genetic data for commercial pharmaceutical research.
The company must assess whether the proposed secondary use is compatible with the original legal basis, consent arrangements, data-protection requirements and applicable research rules.
It cannot automatically assume that initial participation authorises every future use.
9. Biotechnology patents and intellectual property rights
Biotechnology innovation is also protected under Ukrainian intellectual property legislation.
The principal statute is Law No. 3687-XII on the Protection of Rights to Inventions and Utility Models.
Patent protection may be relevant to:
Recombinant proteins.
Biotechnological manufacturing processes.
Engineered microorganisms.
Pharmaceutical compositions.
Certain gene-related inventions.
Diagnostic technologies.
Biotechnology equipment.
However, patentability is not automatic.
An invention must satisfy the applicable legal requirements, including novelty, inventive step and industrial applicability, subject to statutory exclusions.
Important distinction
A scientific discovery of a naturally occurring biological phenomenon is not necessarily a patentable invention.
A technically developed biological process or modified biological material may qualify if it meets the statutory requirements.
Patent protection also does not replace regulatory authorisation. A patented biological medicine still needs the necessary marketing approval.
10. Environmental protection and agricultural biotechnology
Agricultural biotechnology is particularly important to Ukraine because of the country's substantial agricultural sector.
Regulation covers:
Genetically modified seeds.
GM crops.
Agricultural field trials.
GMO-containing animal feed.
Food products produced using GMOs.
Transport and storage of genetically modified materials.
The relevant environmental and food-safety framework includes Law No. 2059-VIII on Environmental Impact Assessment, food-safety legislation and the new GMO regulatory statute.
Environmental risk assessment
Authorities must consider the potential consequences of releasing genetically modified organisms into the environment.
Relevant factors include:
Potential effects on non-target organisms.
Possibility of gene transfer.
Biodiversity consequences.
Risks of cross-pollination.
Effects on agricultural ecosystems.
Persistence of genetically modified organisms.
Possibility of unintended environmental consequences.
The precautionary approach is particularly important where scientific evidence does not completely resolve the possible environmental risks.
11. International and European legal framework
Ukraine's biotechnology regulation is influenced by international biosafety and trade obligations.
| International instrument | Legal significance |
|---|---|
| Cartagena Protocol on Biosafety | International framework for safe handling and movement of living modified organisms |
| Convention on Biological Diversity | Biodiversity conservation and sustainable use |
| WTO agreements | International trade and permissible health and environmental restrictions |
| TRIPS Agreement | Minimum standards for intellectual property protection |
| EU–Ukraine Association Agreement | Approximation of Ukrainian legislation to relevant EU standards |
| European Convention on Human Rights | Human dignity, privacy and protection of individual rights |
A. Cartagena Protocol
The Cartagena Protocol is particularly relevant to international movements of living modified organisms.
It addresses biosafety concerns associated with transboundary movements, handling and use of living modified organisms.
B. European Union alignment
Ukraine's new GMO legislation represents an important step towards alignment with European regulatory principles.
The legislative changes introduced a more structured system of GMO registration, traceability, labelling and state control.
C. International trade
GMO imports and exports are subject to the relevant Ukrainian registration and control requirements.
Ukraine has also notified WTO quantitative restrictions associated with its new GMO legislation. The WTO records identify restrictions concerning unregistered GMOs, transit and genetically modified maize, with relevant statutory exceptions.
Офіційний портал Верховної Ради України+4
12. Important case laws relating to biotechnology regulation in Ukraine
An important research qualification is necessary: Ukrainian reported judicial decisions specifically interpreting the new Law No. 3339-IX are limited because it only became fully effective in September 2026. Therefore, the following cases are relevant through pharmaceutical patent protection, informed consent, medical privacy and scientific evidence. They should not be misrepresented as direct judgments under the new GMO statute.
Case 1. Mayboroda v. Ukraine (2023)
European Court of Human Rights
Application No.: 14709/07
Judgment date: 13 April 2023
Legal provision: Article 8, European Convention on Human Rights.
Facts:
The applicant underwent emergency surgery during which her kidney was removed. She argued that she had not been properly informed about the removal and had not given informed consent to that particular intervention.
Legal issue:
Whether Ukraine had fulfilled its positive obligation to protect the patient's right to informed consent through an appropriate legal and regulatory framework.
Judgment:
The European Court of Human Rights found a violation of Article 8.
It identified shortcomings in the protection of the patient's informed-consent rights.
Importance for biotechnology law:
The judgment is relevant to:
Experimental gene therapies.
Stem-cell treatment.
Organ transplantation.
Regenerative medicine.
Human biological sample collection.
Innovative medical interventions.
Biotechnology researchers and healthcare institutions must ensure that consent is meaningful and sufficiently informed.
Source:
Case 2. M.K. v. Ukraine (2022)
European Court of Human Rights
Application No.: 24867/13
Judgment date: 15 September 2022
Legal provision: Article 8, European Convention on Human Rights.
Facts:
The applicant underwent HIV testing during a medical examination connected with her military service.
She complained that she had not been properly informed about the test results and that her HIV-positive status had been disclosed to third parties, including her military unit.
Legal issue:
Whether the handling and disclosure of sensitive medical information violated the right to respect for private life.
Judgment:
The European Court examined the failure to communicate the test result properly and its disclosure to third parties, finding a violation of Article 8.
Importance for biotechnology law:
This decision has significant implications for:
Genetic testing.
DNA databases.
Genomic research.
Predictive genetic testing.
Genetic disease screening.
Confidentiality of biotechnology research participants.
The decision supports the principle that sensitive biological and medical information must receive effective legal protection.
Source:
LawEuro
Case 3. Supreme Court of Ukraine – Case No. 911/165/18
Biotechnology-related patent precedent
Court: Commercial Cassation Court within the Supreme Court.
Judgment: 5 March 2026.
Facts:
The dispute concerned a patented invention titled Substituted oxazolidinones and their use for preventing blood clotting.
The patent holder sought to prevent unauthorised use of the invention and sought the removal and destruction of imported rivaroxaban pharmaceutical substance.
The defendant argued that the use was for scientific or experimental purposes.
Legal issue:
Whether the scientific-research and experimental-use exception could protect the defendant from patent infringement liability.
Judgment:
The Supreme Court held that merely claiming scientific or experimental use was insufficient.
The party relying on the exception had to provide evidence of genuine scientific activity, appropriate personnel, research facilities and a quantity of material consistent with the claimed research purpose.
The Court also recognised the availability of an injunction as a proper remedy for infringement of patent rights.
Importance for biotechnology law:
This case is particularly relevant to:
Biotechnology pharmaceutical research.
Recombinant drug development.
Biological medicine manufacturing.
Experimental pharmaceutical compounds.
Research exemptions in biotechnology patents.
Commercial exploitation of patented inventions.
It demonstrates that scientific research does not automatically provide immunity from patent infringement.
Source:
КГС ВС
Case 4. Supreme Court of Ukraine – Case No. 522/20005/16-c (2019)
Subject: Molecular-genetic evidence and parentage proceedings.
This decision is relevant to the evidentiary use of genetic testing in judicial proceedings.
Molecular-genetic examinations can assist courts in determining biological relationships.
The legal significance of such evidence includes:
Reliability of DNA testing.
Admissibility of expert evidence.
Proper appointment of scientific examinations.
Assessment of expert conclusions.
Protection of the interests of children and other participants.
The Supreme Court referred to this decision in its later discussion of genetic examination procedures in Case No. 234/11147/20.
Importance for biotechnology law:
It demonstrates the relationship between scientific evidence, genetic testing and judicial decision-making.
The case should be understood as an evidentiary precedent, rather than a decision concerning GMO market authorisation.
supreme.court.gov.ua
13. Regulatory liability and enforcement
Biotechnology businesses may face administrative, civil and, where the statutory elements are satisfied, criminal liability.
A. Administrative liability
Potential violations include:
Placing unregistered GMOs on the market.
Failure to comply with applicable labelling requirements.
Breach of biosafety conditions.
Failure to maintain required traceability records.
Unauthorised genetic engineering activities.
Obstruction of lawful regulatory inspections.
Depending on the violation, authorities may impose statutory administrative or other regulatory measures.
B. Civil liability
Civil liability may arise where biotechnology activities cause legally recognised harm.
Examples include:
Environmental contamination.
Damage caused by defective biological products.
Breach of contractual research obligations.
Patent infringement.
Unlawful disclosure of genetic information.
Injury resulting from unsafe medical treatment.
C. Criminal liability
Criminal liability may arise under applicable provisions of the Criminal Code of Ukraine, depending on the circumstances.
Potentially relevant offences include violations involving environmental pollution, serious breaches of sanitary requirements, professional negligence and other conduct satisfying the elements of a criminal offence.
Criminal responsibility cannot be imposed merely because a biotechnology experiment produces an unsuccessful result. The relevant offence and its legal elements must be established.
14. Major legal challenges in Ukrainian biotechnology regulation
Several important challenges remain.
1. Regulation of CRISPR gene editing
Modern gene-editing technologies create difficult questions about whether particular organisms fall within the statutory definition of GMOs and what regulatory treatment applies.
2. Synthetic biology
Synthetic organisms and engineered biological systems may create risks that are not adequately addressed by conventional regulatory categories.
3. Genomic privacy
The collection and commercial use of genetic information raise concerns about consent, confidentiality and discrimination.
4. Regenerative medicine
Stem-cell products and tissue-engineered therapies require clear classification, safety assessment and clinical oversight.
5. Biotechnology patent disputes
Disagreements may arise over inventorship, biological materials, research exemptions and the commercial exploitation of patented inventions.
6. Regulatory coordination
Different authorities supervise medical products, environmental safety, agricultural products and genetic engineering. Effective coordination is essential.
7. European regulatory harmonisation
Ukraine must continue developing its implementing regulations, technical infrastructure and inspection capacity to support alignment with European standards.
8. War-related biological security
Damage to research laboratories, interruptions in cold-chain infrastructure, biological sample storage and hazardous-material management create additional regulatory and institutional challenges.
15. Practical compliance framework for biotechnology companies
A biotechnology company intending to operate in Ukraine should consider the following compliance sequence.
Biotechnology regulatory compliance pathway
Identify the biotechnology activity
Determine whether the project concerns genetic engineering, pharmaceuticals, agriculture, food, genomic research or industrial biotechnology.
Determine regulatory classification
Identify the applicable statutory definitions, authorisations and competent authorities.
Conduct scientific risk assessment
Assess biological, environmental, health and genetic risks.
Obtain necessary approvals
Complete relevant GMO registrations, clinical-trial approvals, medicinal-product registrations and other permissions.
Establish safety and quality systems
Implement applicable GMP, laboratory containment, documentation and quality-control procedures.
Protect personal and genetic information
Establish appropriate consent, confidentiality, data-security and access-control mechanisms.
Maintain regulatory records
Preserve registration documents, testing records, traceability information and inspection documentation.
Monitor continuing compliance
Review changes in legislation, regulatory decisions, product safety and reporting obligations.
16. Conclusion
Biotechnology Regulatory Law in Ukraine represents an intersection of constitutional law, environmental law, pharmaceutical regulation, intellectual property, public health, scientific research and international trade law.
Law No. 3339-IX is a particularly important development because it establishes a modern framework for genetic engineering activities and the state control of genetically modified organisms and products.
The Ukrainian regulatory system seeks to achieve several objectives simultaneously:
Encourage biotechnology innovation.
Protect human health.
Maintain environmental and genetic safety.
Ensure responsible commercialisation.
Protect genetic and medical information.
Safeguard intellectual property.
Establish accountability for regulatory violations.
Harmonise national standards with European requirements.
The judicial decisions in Mayboroda v. Ukraine, M.K. v. Ukraine and Supreme Court Case No. 911/165/18 provide important legal principles concerning informed consent, medical privacy and biotechnology-related patent enforcement.
Ultimately, the future development of Ukrainian biotechnology law will depend on effective implementation of its new GMO legislation, scientifically sound regulatory procedures, independent oversight and adequate judicial protection.
17. Important primary legal research sources
For further academic research, the following official and institutional resources are useful:
Law No. 3339-IX – Genetic Engineering and GMO Regulation.
Law on Personal Data Protection.
Fundamentals of Healthcare Legislation.
Supreme Court of Ukraine – Judicial Practice.
European Court of Human Rights – HUDOC Database.
World Intellectual Property Organization.
Biosafety Clearing-House – Cartagena Protocol.
Academic note: For a dissertation or legal research publication, distinguish direct Ukrainian biotechnology precedents from analogous healthcare, privacy, pharmaceutical and patent decisions. This distinction is especially important when discussing the newly effective Law No. 3339-IX.

comments